Pathway Diagram
flowchart TD
GPT["GPT"]
style GPT fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
Carcinoma["Carcinoma"]
GPT -->|"associated with"| Carcinoma
Fibrosis["Fibrosis"]
GPT -->|"activates"| Fibrosis
Als["Als"]
GPT -->|"activates"| Als
Ms["Ms"]
GPT -->|"activates"| Ms
Hepatocellular_Carcinoma["Hepatocellular Carcinoma"]
GPT -->|"associated with"| Hepatocellular_Carcinoma
Insulin_Resistance["Insulin Resistance"]
GPT -.->|"inhibits"| Insulin_Resistance
Fatty_Liver["Fatty Liver"]
GPT -->|"activates"| Fatty_Liver
ELAVL1["ELAVL1"]
GPT -->|"associated with"| ELAVL1
GOT1["GOT1"]
GOT1 -->|"associated with"| GPT
SQSTM1["SQSTM1"]
SQSTM1 -->|"associated with"| GPT
GPX4["GPX4"]
GPX4 -->|"associated with"| GPT
style Carcinoma fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Fibrosis fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Als fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Ms fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Hepatocellular_Carcinoma fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Insulin_Resistance fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style Fatty_Liver fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
style ELAVL1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
style GOT1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
style SQSTM1 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
style GPX4 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0Overview
GPT (also known as Alanine Aminotransferase or ALT) is a pyridoxal phosphate-dependent aminotransferase enzyme primarily expressed in the liver, with lower expression in kidney, heart, skeletal muscle, and brain tissue1ALT isoforms in neuronal energy metabolismOpen reference[^1]. While classically considered a clinical marker for liver injury, emerging research has revealed important functions for ALT in systemic metabolism and its dysregulation in neurodegenerative diseases2Liver-brain axis in neurodegenerationOpen reference through the liver-brain axis[^6].
| GPT — Alanine Transaminase | |
|---|---|
| Gene Symbol | GPT |
| Full Name | Alanine Aminotransferase |
| Chromosome | 8q24.3 |
| NCBI Gene ID | [2595](https://www.ncbi.nlm.nih.gov/gene/2595) |
| OMIM | 613208 |
| Ensembl ID | ENSG00000149806 |
| UniProt ID | [P24259](https://www.uniprot.org/uniprot/P24259) |
| Associated Diseases | [Liver Disease](/diseases/fatty-liver-disease), [Metabolic Syndrome](/mechanisms/metabolic-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
Gene and Protein Structure
The GPT gene is located on chromosome 8q24.3 and encodes a protein of approximately 496 amino acids. GPT exists as a homodimer, with each monomer containing a pyridoxal phosphate (PLP) cofactor bound at an active site lysine residue[^1]. The enzyme catalyzes the reversible transamination between alanine and α-ketoglutarate, producing pyruvate and glutamate:
Alanine + α-Ketoglutarate ↔ Pyruvate + Glutamate
This reaction is central to the alanine-glucose cycle (Cahill cycle), which links hepatic gluconeogenesis with peripheral tissue metabolism.
Enzyme Characteristics
| Property | Value |
|---|---|
| EC Number | 2.6.1.2 |
| Cofactor | Pyridoxal phosphate (PLP) |
| Substrate | L-alanine + α-ketoglutarate |
| Product | Pyruvate + L-glutamate |
| Tissue Distribution | Liver > Kidney > Heart >> Brain |
| Molecular Weight | ~55 kDa per subunit |
Isoforms and Tissue Distribution
Two ALT isoforms have been identified:
-
ALT1 (GPT1): Cytosolic isoform, widely expressed
-
ALT2 (GPT2): Mitochondrial isoform, enriched in liver, muscle, and brain[^11]
Both isoforms are present in the brain, with differential expression across brain regions. ALT2 (mitochondrial) is particularly relevant to neuronal energy metabolism.
Function
Primary Metabolic Functions
GPT plays several essential metabolic roles[^1]:
-
Amino Acid Metabolism: ALT catalyzes the reversible transfer of amino groups between alanine and α-ketoglutarate, contributing to nitrogen metabolism and the urea cycle[^11].
-
Gluconeogenesis: During fasting, ALT facilitates hepatic gluconeogenesis by converting alanine-derived carbon to glucose. This is critical for maintaining blood glucose levels during prolonged fasting.
-
Alanine-Glucose Cycle (Cahill Cycle): ALT is a key enzyme in this cycle:
-
Muscle releases alanine from transamination of glycolytic intermediates
-
Liver takes up alanine and converts it to pyruvate via ALT
-
Pyruvate is used for gluconeogenesis
-
Glucose returns to muscle
-
-
Intermediary Metabolism: ALT connects carbohydrate and amino acid metabolism, allowing cells to adapt to changing energy demands.
-
Nitrogen Metabolism: Part of hepatic nitrogen disposal and detoxification.
Role in Neurons
In neurons, ALT (particularly the mitochondrial ALT2 isoform) contributes to:
-
Energy metabolism during high metabolic demand
-
Neurotransmitter synthesis (glutamate cycle)
-
Response to metabolic stress
-
Mitochondrial function maintenance[^11]
In the brain, GPT is expressed at low levels in:
-
Cerebral cortex (pyramidal neurons)
-
Cerebellum (Purkinje cells)
-
Hippocampus (CA1-CA3 neurons)
Brain GPT may serve local nitrogen metabolism and neurotransmitter precursor synthesis.
The Liver-Brain Axis
The liver-brain axis represents a critical bidirectional communication pathway whereby hepatic dysfunction can influence brain function and vice versa[^6]. ALT serves as both a marker and potential mediator of this axis in neurodegeneration.
Mechanisms of Liver-Brain Communication
-
Circulating Metabolites: The liver produces hepatokines (liver-derived signaling proteins) that affect brain function. Liver dysfunction alters the secretome, impacting neuronal survival[^10].
-
Inflammatory Mediators: Liver disease increases circulating pro-inflammatory cytokines (IL-6, TNF-α) that can cross the blood-brain barrier and trigger neuroinflammation[^4].
-
Ammonia Detoxification: The liver detoxifies ammonia via the urea cycle. Impaired liver function leads to hyperammonemia, which is neurotoxic and can contribute to hepatic encephalopathy[^6].
-
Xenobiotic Metabolism: The liver clears circulating toxins and metabolites. Impaired clearance allows potentially neurotoxic compounds to accumulate[^5].
-
Autophagy: The liver plays a key role in systemic autophagy. Liver dysfunction can impair clearance of misfolded proteins systemically, potentially affecting brain protein clearance[^6].
ALT and Neurodegenerative Diseases
Alzheimer’s Disease
Multiple studies have linked ALT dysregulation to Alzheimer’s disease pathogenesis[^3][^19]:
-
Metabolic Syndrome: Elevated ALT is associated with metabolic syndrome, a known risk factor for AD. Insulin resistance and dyslipidemia contribute to amyloidogenesis and tau pathology[^4][^13].
-
Amyloid-β Metabolism: The liver produces apolipoproteins that influence Aβ clearance. Liver dysfunction can impair this clearance mechanism[^5].
-
Tau Pathology: ALT elevation correlates with tau pathology in some studies, possibly reflecting shared metabolic dysfunction[^12].
-
Cognitive Decline: Cohort studies have shown that elevated ALT in midlife is associated with faster cognitive decline and increased AD risk[^2][^17].
Parkinson’s Disease
The relationship between ALT and Parkinson’s disease involves multiple pathways[^8][^14]:
-
Metabolic Factors: ALT elevation is associated with altered PD risk in some cohorts, possibly reflecting compensation for altered metabolism.
-
Gut-Liver-Brain Axis: Liver dysfunction may contribute to PD through altered xenobiotic metabolism and increased intestinal permeability[^18].
-
Mitochondrial Function: ALT2 is mitochondrially localized, and its dysregulation may affect neuronal energy metabolism[^15].
Huntington’s Disease
ALT and other liver enzymes are often abnormal in Huntington’s disease[^9]:
-
Metabolic Dysfunction: Elevated ALT correlates with disease progression and may reflect hepatic involvement or altered energy metabolism.
-
Systemic Changes: HD patients show metabolic abnormalities including altered gluconeogenesis and muscle wasting, with ALT reflecting these systemic changes.
| Disease | Association | Mechanism |
|---|---|---|
| Non-Alcoholic Fatty Liver Disease (NAFLD) | Elevated ALT | Hepatic steatosis, inflammation |
| Metabolic Syndrome | Elevated ALT | Insulin resistance, adiposity |
| Alzheimer’s Disease | Mixed associations | Liver-brain axis, metabolism |
| Parkinson’s Disease | Mixed associations | Metabolic compensation, gut-liver axis |
| Huntington’s Disease | Elevated ALT | Systemic metabolic dysfunction |
Liver Disease
GPT is a key clinical marker for:
-
Viral hepatitis (HBV, HCV): Elevated GPT indicates hepatocellular injury
-
Non-alcoholic fatty liver disease (NAFLD): GPT elevation correlates with steatosis severity
-
Alcoholic liver disease: GPT elevation, often with AST/GPT ratio > 2
-
Drug-induced liver injury: Monitoring GPT is essential for drug safety
Metabolic Syndrome
Elevated ALT is strongly associated with:
-
Insulin resistance: GPT predicts development of type 2 diabetes
-
Obesity: Especially central/visceral adiposity
-
Dyslipidemia: Elevated triglycerides, low HDL
-
Hypertension: Metabolic syndrome components cluster together
Role in Neurodegeneration: Mechanisms
Systemic Inflammation
Elevated GPT reflects hepatic inflammation that can affect the brain:
-
Pro-inflammatory cytokines (IL-6, TNF-α) cross the blood-brain barrier
-
Microglial activation in response to peripheral inflammation
-
Exacerbation of neuroinflammation in existing neurodegenerative processes[^4]
Impaired Autophagy
The liver’s role in systemic autophagy links to neurodegeneration:
-
Reduced clearance of misfolded proteins
-
Accumulation of protein aggregates
-
Impaired mitophagy affecting neuronal mitochondria[^6]
Lipid Metabolism
GPT elevation often accompanies dyslipidemia:
-
Altered brain lipid composition
-
Impaired myelin maintenance
-
Synaptic membrane dysfunction
Glucose Metabolism
The GPT-metabolic syndrome connection affects brain energy:
-
Reduced glucose uptake
Diagnostic Significance
ALT is primarily used as a clinical marker for liver injury:
-
Acute Liver Injury: Sharp ALT elevation indicates hepatocyte damage
-
Chronic Liver Disease: Moderately elevated ALT suggests ongoing hepatic inflammation
-
NAFLD/NASH: ALT elevation is often the first indicator of metabolic liver disease
-
Drug-Induced Liver Injury: ALT is a sensitive marker for drug hepatotoxicity
In the context of neurodegeneration, ALT serves as an indirect marker of:
-
Metabolic health
-
Systemic inflammation
-
Liver-brain axis integrity
Therapeutic Implications
Targeting the Liver-Brain Axis
Understanding ALT’s role in the liver-brain axis suggests potential therapeutic approaches[^4]:
-
Metabolic Modulation: Improving insulin sensitivity and reducing metabolic syndrome may benefit both liver and brain.
-
Anti-inflammatory Therapy: Reducing systemic inflammation could protect against liver-mediated neuroinflammation.
-
Hepatoprotective Agents: Protecting liver function may help maintain the liver-brain axis.
-
Lifestyle Interventions: Diet and exercise can lower ALT and improve brain health.
Monitoring in Neurodegenerative Diseases
-
GPT as biomarker for metabolic comorbidities
-
Baseline and monitoring in patients on potentially hepatotoxic medications
-
Predicting response to certain therapeutic agents
In the brain, GPT supports neuronal metabolism:
-
Provides carbon skeletons for the TCA cycle
-
Supports astrocyte-neuron metabolic coupling
-
May influence neurotransmitter glutamate levels
Cross-links
-
Proteins/GPT — Protein page
-
Mechanisms/Glutamate-Toxicity — Excitotoxicity pathways
-
Mechanisms/Liver-Brain Axis — Liver-brain communication
-
Mechanisms/Metabolic-Syndrome — Metabolic contributions to neurodegeneration
-
Alzheimer’s Disease — AD overview
-
Parkinson’s Disease — PD overview
-
APOE — AD risk gene
-
SLC2A1 (GLUT1) — Glucose transporter
-
PPARG — Metabolic regulator
-
APP — Amyloid precursor protein
-
Alpha-synuclein — PD protein
References
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.